NASDAQ:TOCA - Tocagen Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.78
▼ -0.09 (-3.14%)
Get New Tocagen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TOCA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TOCA

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Tocagen in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $2.78.

This chart shows the closing price for TOCA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Tocagen. This rating has held steady since February 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 8 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 7 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/20/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/18/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/20/2020Chardan CapitalReiterated RatingHold$1.00N/A
11/25/2019Chardan CapitalReiterated RatingHoldHigh
11/14/2019HC WainwrightReiterated RatingHoldMedium
11/13/2019Chardan CapitalReiterated RatingHold$1.00High
10/17/2019Cantor FitzgeraldReiterated RatingNeutralHigh
10/3/2019Chardan CapitalDowngradeHold$1.00High
9/13/2019CitigroupDowngradeBuy ➝ Neutral$20.00 ➝ $1.00High
9/13/2019Chardan CapitalDowngradeBuy ➝ Neutral$1.00High
9/12/2019B. RileyDowngradeBuy ➝ NeutralHigh
9/12/2019LADENBURG THALM/SH SHDowngradeBuy ➝ NeutralHigh
9/12/2019HC WainwrightDowngradeBuy ➝ Neutral$3.32N/A
9/12/2019Cantor FitzgeraldDowngradeOverweight ➝ NeutralN/A
9/12/2019Robert W. BairdDowngradeOutperform ➝ NeutralN/A
8/9/2019HC WainwrightReiterated RatingBuyHigh
5/30/2019CitigroupInitiated CoverageBuyHigh
5/22/2019SVB LeerinkSet Price TargetHold$5.00High
5/22/2019Chardan CapitalReiterated RatingBuy$10.00High
5/14/2019Chardan CapitalSet Price TargetBuy$25.00Low
5/9/2019HC WainwrightReiterated RatingBuy$14.50High
4/25/2019Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$28.00High
4/23/2019Chardan CapitalReiterated RatingBuyHigh
4/15/2019SVB LeerinkInitiated CoverageMkt Perform ➝ Market Perform$11.00Medium
1/18/2019Robert W. BairdInitiated CoverageOutperform ➝ Outperform$20.00Medium
12/31/2018B. RileyInitiated CoverageBuy ➝ Buy$22.00 ➝ $22.00Medium
11/12/2018HC WainwrightSet Price TargetBuy$15.00High
9/20/2018B. RileyBoost Price TargetBuy ➝ Buy$15.00 ➝ $22.00Low
9/4/2018CitigroupInitiated CoverageBuy$27.00High
8/30/2018Chardan CapitalInitiated CoverageBuy ➝ Buy$30.00High
6/27/2018LADENBURG THALM/SH SHInitiated CoverageBuy$20.00Medium
6/11/2018HC WainwrightInitiated CoverageBuy$14.50Low
5/16/2018B. RileyInitiated CoverageBuy$15.00High
7/25/2017Stifel NicolausReiterated RatingBuy$24.00Low
5/15/2017Stifel NicolausInitiated CoverageBuy$24.00Medium
5/15/2017SVB LeerinkInitiated CoverageMkt Perform$19.00Medium
5/9/2017Evercore ISIReiterated RatingOutperform$28.00Low
5/8/2017SVB LeerinkInitiated CoverageMkt Perform ➝ Market Perform$19.00High
5/8/2017Stifel NicolausInitiated CoverageBuy ➝ Buy$24.00Medium
(Data available from 10/18/2016 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/22/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/20/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/20/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/19/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/18/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/18/2021

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Tocagen logo
Tocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The company's lead product candidate is Toca 511 & Toca FC that is under Phase III clinical trial for recurrent high-grade glioma. It is also developing Toca 511 & Toca FC in a Phase Ib clinical trial for intravenous treatment of advanced cancers. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets. The company has a license agreement with ApolloBio to develop and commercialize Toca 511 & Toca FC; and a collaboration agreement with NRG Oncology to develop a clinical trial utilizing Toca 511 & Toca FC for the treatment of patients with newly diagnosed glioblastoma. Tocagen Inc. was founded in 2007 and is based in San Diego, California.
Read More

Today's Range

Now: $2.78
Low: $2.76
High: $2.87

50 Day Range

MA: $32.24
Low: $1.26
High: $41.03

52 Week Range

Now: $2.78
Low: $0.42
High: $6.77

Volume

642,356 shs

Average Volume

1,472,422 shs

Market Capitalization

$66.49 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.01

Frequently Asked Questions

What sell-side analysts currently cover shares of Tocagen?

The following Wall Street sell-side analysts have issued reports on Tocagen in the last year:
View the latest analyst ratings for TOCA.

What is the current price target for Tocagen?

0 Wall Street analysts have set twelve-month price targets for Tocagen in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Tocagen in the next year.
View the latest price targets for TOCA.

What is the current consensus analyst rating for Tocagen?

Tocagen currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for TOCA.

How do I contact Tocagen's investor relations team?

Tocagen's physical mailing address is 4242 CAMPUS POINT COURT SUITE 500, SAN DIEGO CA, 92121. The company's listed phone number is 858-412-8400 and its investor relations email address is [email protected] The official website for Tocagen is www.tocagen.com.